Citations

Showing 10 of 108162 citations.

Takayasu Arteritis: a Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments
Dua, Anisha B. , Kalot, Mohamad A. , Husainat, Nedaa , Byram, Kevin , Springer, Jason , James, Karen , Lin, Yih Chang, Turgunbaev, Marat, Villa‐Forte, Alexandra, Abril, Andy , Langford, Carol A. , Maz, Mehrdad , Husainat, Nedaa M , Springer, Jason M , Kalot, Mohamad A , Dua, Anisha B , Chung, Sharon A. , Mustafa, Reem A

Mayo Clinic

ACR Open Rheumatology | January 29, 2021 | Volume: 3 | Issue: 2 | Pages: 80-90

10.1002/acr2.11186 | PMID 33512784 Get It

ObjectiveTakayasu’s arteritis (TAK) is a granulomatous large‐vessel vasculitis primarily affecting the aorta and its proximal branches. TAK can be a difficult disease to diagnose and manage given the rarity of the disease as well as current limitations in biomarkers, imperfect imaging modalities, and few randomized controlled trials.MethodsIn developing the American College of Rheumatology/Vasculitis Foundation guideline for the management of TAK, we performed an extensive systematic literature review to guide our recommendations. We included RCTs first. When RCTs were not available, we included observational studies that reported on patient‐important outcomes for the intervention and comparison. When studies with comparative data were not available, we included case series that present patient‐important outcomes for either the intervention or the comparison.ResultsThree hundred forty‐seven articles were included for full review to answer 27 population, intervention, comparison, and outcome questions related to TAK. Ten studies were evaluated that addressed the use of glucocorticoids (GCs), non‐GC nonbiologic therapies, as well as biologics in treating TAK. A total of 33 studies, including 8 comparative studies, were included to determine the test accuracy of commonly available diagnostic tests for TAK.ConclusionThis comprehensive systematic review synthesizes and evaluates the benefits and harms of different treatment options and the accuracy of commonly used tests for the management of TAK.
Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments
Lin, Yih Chang, Kalot, Mohamad A. , Husainat, Nedaa , Byram, Kevin , Dua, Anisha B. , James, Karen , Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Abril, Andy , Langford, Carol A. , Maz, Mehrdad , Husainat, Nedaa M , Springer, Jason M , Mustafa, Reem A , Kalot, Mohamad A , Dua, Anisha B , Chung, Sharon A.

Mayo Clinic

ACR Open Rheumatology | January 29, 2021 | Volume: 3 | Issue: 2 | Pages: 91-100

10.1002/acr2.11189 | PMID 33512781 Get It

ObjectiveThe object of this study was to analyze the benefits and harms of different treatment options and to analyze test accuracy used in the evaluation of patients with primary systemic polyarteritis nodosa (PAN).MethodsA systematic search of published English‐language literature was performed in Ovid Medline, PubMed, Embase, and the Cochrane Library from the inception of each database through August 2019. Articles were screened for suitability in addressing patient, intervention, comparison, and outcome questions, with studies presenting the highest level of evidence given preference.ResultsOf 137 articles selected for data abstraction, we analyzed 21 observational studies and seven randomized controlled trials (RCTs). The results showed indirect evidence that a deep skin biopsy provides good diagnostic accuracy. A combined nerve and muscle biopsy should be obtained for patients with PAN with peripheral neuropathy. Cyclophosphamide with high‐dose glucocorticoids (GCs) is effective as an induction treatment for newly diagnosed active and severe PAN. GC monotherapy is adequate in the majority of patients with nonsevere PAN, although it has a high relapse rate with GC taper. There was insufficient data in determining the optimal duration of non‐GC and GC maintenance therapy. Tumor necrosis factor inhibitors are effective treatment for patients with deficiency of adenosine deaminase 2 (DADA2) with stroke and vasculitis manifestations.ConclusionThis comprehensive systematic review synthesizes and evaluates the harms and benefits of different treatment options and the accuracy of commonly used tests for the diagnosis of systemic PAN. Data for diagnosis and management of PAN and DADA2 are mostly limited to observational studies. More high‐quality RCTs are needed.
Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments
Springer, Jason , Kalot, Mohamad A. , Husainat, Nedaa , Byram, Kevin , Dua, Anisha B. , James, Karen , Lin, Yih Chang, Turgunbaev, Marat, Villa‐Forte, Alexandra, Abril, Andy , Langford, Carol A. , Maz, Mehrdad , Springer, Jason M , Husainat, Nedaa M , Byram, Kevin W , Mustafa, Reem A , Kalot, Mohamad A , Dua, Anisha B , Chung, Sharon A.

Mayo Clinic

ACR Open Rheumatology | January 29, 2021 | Volume: 3 | Issue: 2 | Pages: 101-110

10.1002/acr2.11194 | PMID 33512787 Get It

ObjectiveEosinophilic granulomatosis with polyangiitis (EGPA) is part of a group of vasculitides commonly referred to as antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), in addition to granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal‐limited vasculitis. Patients with EGPA characteristically have asthma and marked peripheral eosinophilia with only approximately 30% to 35% of patients being myeloperoxidase (MPO)‐ANCA positive, distinguishing it from other forms of AAV (1,2). The aim of this systematic review is to support the development of the American College of Rheumatology/Vasculitis Foundation guideline for the management of EGPA.MethodsA systematic review was conducted of the literature for seven forms of primary systemic vasculitis (GPA, MPA, EGPA, polyarteritis nodosa, Kawasaki disease, giant cell arteritis, and Takayasu arteritis). The search was done for articles in English using Ovid Medline, PubMed, Embase, and the Cochrane Library. Articles were screened for suitability in addressing population/patients, intervention, comparator, and outcomes (PICO) questions, with studies presenting the highest level of evidence given preference. Two independent reviewers conducted a title/abstract screen and full‐text review for each eligible study.ResultsThe initial search, conducted in August 2019, included 13 800 articles, of which 2596 full‐text articles were reviewed. There were 190 articles (addressing 34 PICO questions) reporting on the diagnosis and management of EGPA.ConclusionThis comprehensive systematic review synthesizes and evaluates the accuracy of commonly used tests for EGPA as well as benefits and toxicities of different treatment options.
Enoxaparin Dose Requirements to Achieve Therapeutic Low–molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children
Wysocki, E, Steinbrenner, Jenny, Tyrrell, Laura , Cloyd, Colleen , Wysocki, Emma L., Kuhn, Alexis , Abdel‐Rasoul, Mahmoud , Dunn, Amy L.

Mayo Clinic

Journal of Pediatric Hematology/Oncology | January 29, 2021 | Volume: 43 | Issue: 7 | Pages: e946-e950

10.1097/mph.0000000000002066 | PMID 33512867 Get It

Introduction: Enoxaparin is commonly used to treat pediatric thrombosis. Several small retrospective studies have suggested that infants and young children require higher enoxaparin doses to achieve therapeutic anti-factor Xa levels compared with adults. Materials and Methods: This is a retrospective study of hospitalized children who received enoxaparin for the treatment of thrombosis at a free-standing children’s hospital. The primary objective was to ascertain the enoxaparin dose required to achieve an anti-factor Xa level of 0.5 to 1.0 U/mL among 4 age groups in a large cohort of infants and young children between 60 days and 5 years of age. Results: A total of 176 infants and children were evaluated. The majority of patients were less than 1 year of age (n=104). An inverse relationship between enoxaparin dose needed to achieve therapeutic anti-factor Xa levels and patient age was noted, particularly in the first year of life. Patients who were 60 days to less than 7 months at the time of enoxaparin initiation (n=73) required the highest mean dose among the age groups at 1.73 mg/kg subcutaneously every 12 hours (P<0.0001). Conclusion: Infants and young children require higher doses of enoxaparin to achieve therapeutic anti-factor Xa levels compared with adults.
The Top 50 Most‐Cited Shoulder Arthroscopy Studies
Pollock, Jordan R. , McQuivey, Kade S. , Bingham, Joshua S. , Pollock, Jordan Riley , Moore, M. Lane

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | January 29, 2021 | Volume: 3 | Issue: 1 | Pages: No page available

10.1016/j.asmr.2020.09.011 | PMID 33615275 Get It

Purpose To determine the 50 most frequently cited studies in the orthopaedic shoulder arthroscopy literature and to conduct a bibliometric analysis of these studies. Methods The Clarivate Analytics Web of Knowledge database was used to gather data and metrics using Boolean queries to capture all possible iterations of shoulder arthroscopy research. The search list was sorted so that articles were organized in descending order based on the number of citations and included or excluded based on relevance to shoulder arthroscopy. The information extracted for each article included author name, publication year, country of origin, journal name, article type, and the level of evidence. Results For these 50 studies, the total number of citations was calculated to be 13,910, with an average of 278.2 citations per paper. The most‐cited article was cited 1134 times, whereas the second‐ and third‐most cited articles were cited 920 and 745 times, respectively. All 50 articles were published in English and came from 7 different orthopaedic journals. The United States was responsible for most of the included articles (31), followed by France (9) and Japan (3). Conclusions The majority of the most‐cited articles in shoulder arthroscopy are case series and descriptive studies originating from the United States. In addition, more than one half of the top 50 most‐cited studies were published after 2004, which suggests that article age may be less important in the accumulation of citations for a rapidly growing field like shoulder arthroscopy. Clinical Relevance The top 50 most‐cited studies list will provide researchers, medical students, residents, and fellows with a foundational list of the most important and influential academic contributions to shoulder arthroscopy.
Here to chair: Gender differences in the path to leadership
Sethuraman, Kinjal , Lin, Michelle , Rounds, Kirsten, Fang, Andrea , Lall, Michelle D. , Parsons, Melissa , Linden, Judith A. , Gursahani, Kamal, Perman, Sarah M. , Dobiesz, Valerie , Sethuraman, Kinjal N , Raukar, Neha, Raukar, Neha P.

Mayo Clinic

Academic Emergency Medicine | January 29, 2021 | Volume: 28 | Issue: 9 | Pages: 993-1000

10.1111/acem.14221 | PMID 33511736 Get It

AbstractObjectiveCareer paths leading to department chair positions are elusive. Women represent only 11% of academic emergency department (ED) chairs. It is unclear whether the pathway to chair is different for men and women; the characteristics, achievements, and qualifications among those who become ED chairs is unknown.MethodsThis study is a cross‐sectional analysis of curriculum vitae (CV) of current ED chairs in departments with Accreditation Council for Graduate Medical Education (ACGME)‐accredited residency programs. Former women chairs were included due to paucity of current women chairs. Statistics were calculated using bivariate and multivariate analysis.ResultsOf 163 eligible chairs, 88 CV (54%) were obtained, including six former women chairs. A majority (86.4%) self‐identified as White/Caucasian, 21.5% were women, 46% were chief residents, 28.4% completed additional postgraduate degrees, and 21.8% were fellowship trained. At time of chair appointment, 58% were professor rank, 53.5% held ED operations roles, and 32% served as vice chair. Women were more likely to be in educational (53% vs. 22%) versus operational (26% vs. 61%, p = 0.02) roles. Women obtained more advanced degrees (47% vs. 25%, p = 0.02), were awarded more nonfederal grants (median = 7 vs. 3, p = 0.04), and achieved more national committee leadership (median = 4 vs. 1, p = 0.02). There were no gender differences in fellowship training, awards, leadership training programs, publications, federal grants, or national/international lectures after adjusting for years in practice.ConclusionWhile the majority of chairs held prior leadership roles in ED operations, only one in five women chairs did, suggesting gender differences in the path to chair attainment. These differences in paths may contribute to persistent gender disparities in ED chairs and may be influenced by career path choices, implicit bias, and structural barriers.
Clear Cell Carcinoid Tumor of the Gallbladder
Nakashima, Yasuaki, Smyrk, Thomas C. , Masuda, Seiji, Konishi, Eiichi

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 127 | Issue: 6 | Pages: 745-747

10.5858/2003-127-745-ccctot | PMID 12741904 Get It

Abstract A golden yellow polyp was detected in the gallbladder of a 64-year-old man who presented with epigastric pain. The lesion was composed of clear polygonal cells arranged in a trabecular and glandular pattern. The tumor invaded through the wall into the perimuscular subserosal layer. Immunohistochemical stains showed that neoplastic cells were positive for chromogranin A, synaptophysin, somatostatin, gastrin, and pancreatic polypeptide and negative for glucagon, serotonin, insulin, S100 protein, and inhibin. This tumor resembles the recently described clear cell endocrine tumors of the gallbladder and pancreas that are associated with von Hippel-Lindau disease. Our patient, however, had neither personal nor family history indicative of von Hippel-Lindau disease. Furthermore, published accounts of clear cell endocrine tumors in von Hippel-Lindau disease describe immunoreactivity for inhibin; the current case was negative for the disease. There may be a subtype of clear cell carcinoid tumor not associated with von Hippel-Lindau disease, which is characterized by its lack of immunoreactivity against inhibin.
Prevalence and Incidence of Cytoplasmic Yellow Bodies in Thyroid Neoplasms
Rothenberg, Harold J., Goellner, John R., Carney, J. Aidan

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 127 | Issue: 6 | Pages: 715-717

10.5858/2003-127-715-paiocy | PMID 12741896 Get It

Abstract Context. —Cytoplasmic yellow bodies are a common and frequent histologic finding in hyalinizing trabecular adenoma of the thyroid gland, a morphologically distinctive neoplasm, and are visible in fine-needle aspiration biopsy of the tumor. Objective. —To determine the prevalence and frequency of cytoplasmic yellow bodies in common thyroid tumors. Design. —Microscopic slides of random cases of papillary carcinoma (61 cases), follicular adenoma (27 cases), and Hürthle cell adenoma (12 cases) were searched for cytoplasmic yellow bodies. Setting and Patients. —Slides were from patients who had undergone surgery at Mayo Clinic, Rochester, Minn, and were obtained from the Mayo Clinic Tissue Registry. Main Outcome Measure. —Presence or absence of cytoplasmic yellow bodies. Results. —Cytoplasmic yellow bodies were found in papillary carcinoma (62%), follicular carcinoma (22%), and Hürthle cell adenoma (83%) but were very infrequent numerically in each tumor type. Conclusions. —Cytoplasmic yellow bodies may be present in papillary carcinoma and in follicular and Hürthle cell adenomas, but because they are uncommon in these tumors, they are unlikely to be found in fine-needle aspiration biopsy smears. Therefore, cytoplasmic yellow bodies are a useful cytomorphologic indicator of hyalinizing trabecular adenoma of the thyroid gland.
Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye
Vaxman, Iuliana , Gertz, Morie A. , Gertz, Morie A , Vaxman, Iuliana

Mayo Clinic

Leukemia & Lymphoma | January 29, 2021 | Volume: 62 | Issue: 7 | Pages: 1544-1553

10.1080/10428194.2021.1873320 | PMID 33508994 Get It

Reply to letter to editor by McCullough
Goyal, Amandeep , Bansal, Pankaj , Bansal, Pankaj

Mayo Clinic

Annals of Medicine | January 29, 2021 | Volume: 53 | Issue: 1 | Pages: 335-336

10.1080/07853890.2021.1878273 | PMID 33511888 Get It